Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             142 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors 2002
 38 Supplement 6 p. S53-S54
2 p.
 artikel
2 Activation of wt p53 protein in normal and tumor cells by a novel anti-cancer drug CHS 828 2002
 38 Supplement 6 p. S109-
1 p.
 artikel
3 alpha2-6-sialylated neolacto-series gangliosides serve as receptors for the anticancer drug rViscumin 2002
 38 Supplement 6 p. S107-S108
2 p.
 artikel
4 A multicenter, phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma 2002
 38 Supplement 6 p. S18-
1 p.
 artikel
5 An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes Awada, A
 2002
 38 Supplement 6 p. 773-778
6 p.
 artikel
6 A novel target for antifolates: the dihydrofolate reductase domain of the G1/S transit controlling protein elF-5A 2002
 38 Supplement 6 p. S105-
1 p.
 artikel
7 Anticancer activity of a 6-base length phosphodiester oligonucleotide, Oligomodulator™BT 99-25, against lymphoma 2002
 38 Supplement 6 p. S168-S169
2 p.
 artikel
8 Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells Lee, J.-U
 2002
 38 Supplement 6 p. 1526-1534
9 p.
 artikel
9 Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts 2002
 38 Supplement 6 p. S62-
1 p.
 artikel
10 A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) 2002
 38 Supplement 6 p. S88-
1 p.
 artikel
11 A phase II trial of an attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant dysplastic oral lesions 2002
 38 Supplement 6 p. S84-
1 p.
 artikel
12 A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer 2002
 38 Supplement 6 p. S77-
1 p.
 artikel
13 A phase I trial of ABT-751, a novel microtubulin inhibitor 2002
 38 Supplement 6 p. S42-
1 p.
 artikel
14 A phase I trial of 17-Allyl-Amino-Geldanamycin (17-AAG) in patients with advanced cancer 2002
 38 Supplement 6 p. S54-S55
2 p.
 artikel
15 A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III) Proctor, S.J
 2002
 38 Supplement 6 p. 795-806
12 p.
 artikel
16 Aromatase inhibitors and inactivators for breast cancer treatment Lonning, P.E
 2002
 38 Supplement 6 p. 47-48
2 p.
 artikel
17 Author index 2002
 38 Supplement 6 p. S175-S188
14 p.
 artikel
18 “Be brilliant!”—a tribute to Tom Connors Newell, Herbie
 2002
 38 Supplement 6 p. 1163-1164
2 p.
 artikel
19 Biological therapy of colorectal cancer de Kleijn, E.M.H.A.
 2002
 38 Supplement 6 p. 1016-1022
7 p.
 artikel
20 Biomarkers of anticancer activity of R115777 in combination with paclitaxel in a human breast cancer model in vitro 2002
 38 Supplement 6 p. S58-
1 p.
 artikel
21 Breast cancer screening in Europe — current status 2002
 38 Supplement 6 p. S37-S39
3 p.
 artikel
22 Brostallicin potentates the antitumor activity of other cytotoxic antineoplastic agents in experimental tumor models 2002
 38 Supplement 6 p. S29-
1 p.
 artikel
23 Ca 15-3 in the follow-up of localised breast cancer Kokko, R
 2002
 38 Supplement 6 p. 1189-1193
5 p.
 artikel
24 Calendar 2002
 38 Supplement 6 p. I-II
nvt p.
 artikel
25 Calendar of Forthcoming Meetings 2002
 38 Supplement 6 p. I-II
nvt p.
 artikel
26 Cancer vaccines based on defined tumor antigens: specificity with an eye on prevention 2002
 38 Supplement 6 p. S9-
1 p.
 artikel
27 Cell cycle perturbations and apoptosis induced by the novel marine compound variolin B 2002
 38 Supplement 6 p. S33-
1 p.
 artikel
28 Cellular responses to DNA topoisomerase I poisons and the TOR kinase inhibitor, rapamycin 2002
 38 Supplement 6 p. S63-
1 p.
 artikel
29 Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer Jakesz, R
 2002
 38 Supplement 6 p. 327-332
6 p.
 artikel
30 Clinical experience of capecitabine in metastatic breast cancer O'Shaughnessy, J
 2002
 38 Supplement 6 p. 10-14
5 p.
 artikel
31 Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification Kim, K
 2002
 38 Supplement 6 p. 75-81
7 p.
 artikel
32 Clinical implications of lymphatic mapping by sentinel node biopsy 2002
 38 Supplement 6 p. S88-S89
2 p.
 artikel
33 CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of non-hodgkin's lymphoma 2002
 38 Supplement 6 p. S150-
1 p.
 artikel
34 Combination of novel sulfonamide anticancer drug, E7070, with CPT-11 “antitumor effect and synergistic mechanism” 2002
 38 Supplement 6 p. S17-S18
2 p.
 artikel
35 Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer Bartelink, H.
 2002
 38 Supplement 6 p. 667-673
7 p.
 artikel
36 Conserved mechanism of CDC45 function in protecting yeast and human cells from DNA damage 2002
 38 Supplement 6 p. S47-
1 p.
 artikel
37 Corrigendum to ‘A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer’ Eur J Cancer 2001, 37, S264–S265. R. Pirker, J. Vansteenkiste, J. Gateley, P. Yates, A. Colowick, J. Musil 2002
 38 Supplement 6 p. 449-
1 p.
 artikel
38 CT-32228: a lysophosphatidic acid acyltransferase-beta (LPAAT-b) inhibitor, induces apoptosis in a variety of solid tumor, leukemia and lymphoma cell lines, but not in normal cells 2002
 38 Supplement 6 p. S96-
1 p.
 artikel
39 D-82318 — a new, synthetic, low molecular weight tubulin inhibitor with potent in vivo antitumor activity 2002
 38 Supplement 6 p. S38-
1 p.
 artikel
40 Design and optimization of topoisomerase poison conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage 2002
 38 Supplement 6 p. S125-
1 p.
 artikel
41 Differential kinetic properties of monomeric and oligomeric phosphorylated c-met 2002
 38 Supplement 6 p. S97-
1 p.
 artikel
42 Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Sinha, P.S
 2002
 38 Supplement 6 p. 1474-1477
4 p.
 artikel
43 Does the method of detection of breast cancer affect subsequent psychiatric morbidity? Burgess, C.C
 2002
 38 Supplement 6 p. 1622-1625
4 p.
 artikel
44 Effect of preoperative radiotherapy on matrilysin gene expression in rectal cancer Kumar, A
 2002
 38 Supplement 6 p. 505-510
6 p.
 artikel
45 Epidemiology and statistics 2002
 38 Supplement 6 p. S87-
1 p.
 artikel
46 Epidemiology — laboratory 2002
 38 Supplement 6 p. S39-S42
4 p.
 artikel
47 Evaluation in vivo of new agents for drug-resistant ovarian and breast carcinomas 2002
 38 Supplement 6 p. S130-
1 p.
 artikel
48 Functional computed tomography in oncology Miles, K.A.
 2002
 38 Supplement 6 p. 2079-2084
6 p.
 artikel
49 Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer Laack, E
 2002
 38 Supplement 6 p. 654-660
7 p.
 artikel
50 Gene expression microarray and 2D proteomic profiling of human ovarian adenocarcinoma cells following treatment with 17AAG, an inhibitor of the molecular chaperone Hsp90 2002
 38 Supplement 6 p. S92-S93
2 p.
 artikel
51 Heat shock protein 27 prevents gamma radiation-induced apoptosis 2002
 38 Supplement 6 p. S145-
1 p.
 artikel
52 Hypoxia as a target for combined modality treatments Wouters, B.G
 2002
 38 Supplement 6 p. 240-257
18 p.
 artikel
53 IDN-5390, an orally active, antiangiogenic taxoid with low toxicity, ideally suited for metronomic dosing 2002
 38 Supplement 6 p. S37-S38
2 p.
 artikel
54 IL-1α gene expression in human endometrial cancer is independent of ovarian steroid receptor expression Singer, C.F
 2002
 38 Supplement 6 p. 76-77
2 p.
 artikel
55 Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing Léger, F.
 2002
 38 Supplement 6 p. 52-56
5 p.
 artikel
56 Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients Del Mastro, L.
 2002
 38 Supplement 6 p. 359-366
8 p.
 artikel
57 Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A Sava, G
 2002
 38 Supplement 6 p. 427-435
9 p.
 artikel
58 Inhibition of MEK/ERK and PI3K/Akt pathways blocks apoptosis suppression signaling of FLT3/ITD 2002
 38 Supplement 6 p. S166-
1 p.
 artikel
59 Inhibition of PI3 kinase causes cell death through a PKB dependent mechanism and growth arrest through a PKB independent mechanism 2002
 38 Supplement 6 p. S162-
1 p.
 artikel
60 Insulin-like growth factor binding protein-6 inhibits neuroblastoma cell proliferation and tumour development Seurin, D
 2002
 38 Supplement 6 p. 2058-2065
8 p.
 artikel
61 Involvement of glutathione S-transferase pi inhibitor TLK199 in myeloproliferation and myelodifferentiation 2002
 38 Supplement 6 p. S88-S89
2 p.
 artikel
62 It's time for chronotherapy! Coudert, B
 2002
 38 Supplement 6 p. 50-53
4 p.
 artikel
63 Lung cancer molecular fingerprinting: expression profiling of gene and protein with cDNA microarray and MALDI-TOF MS 2002
 38 Supplement 6 p. S100-S101
2 p.
 artikel
64 Molecular beacon based photosensitizers for imaging guided cancer therapy 2002
 38 Supplement 6 p. S119-
1 p.
 artikel
65 Natural product-based phosphatase and tubulin-polymerisation inhibitors 2002
 38 Supplement 6 p. S14-
1 p.
 artikel
66 Novel expressed sequences obtained by means of a suppression subtractive hybridisation analysis from the 6q21 region that is frequently deleted in gastric cancer Carvalho, B.
 2002
 38 Supplement 6 p. 1126-1132
7 p.
 artikel
67 Novel nitroimidazoyluracil prodrug derivatives as tumour-selective inhibitors of the angiogenic enzyme thymidine phosphorylase 2002
 38 Supplement 6 p. S104-
1 p.
 artikel
68 Novel splice variants in the ABCC1 (multidrug resistance-associated protein-1) gene in ovarian cancer 2002
 38 Supplement 6 p. S158-S159
2 p.
 artikel
69 Novel 2-step desensitization dosing regimen of intravenous PV701, an oncolytic virus, results in improved tolerability: a phase I study of patients with advanced solid tumours 2002
 38 Supplement 6 p. S155-
1 p.
 artikel
70 Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death Tassone, P.
 2002
 38 Supplement 6 p. 1141-1147
7 p.
 artikel
71 Past, present and future perspectives of colorectal cancer—on the brink of a new era? van Krieken, J.H.J.M
 2002
 38 Supplement 6 p. 855-857
3 p.
 artikel
72 Pemetrexed translational research in patients with previously untreated breast cancer 2002
 38 Supplement 6 p. S25-
1 p.
 artikel
73 PET for in vivo pharmacokinetic and pharmacodynamic measurements Gupta, N
 2002
 38 Supplement 6 p. 2094-2107
14 p.
 artikel
74 p107 Expression in colorectal tumours rises during carcinogenesis and falls during invasion Wu, F
 2002
 38 Supplement 6 p. 1838-1848
11 p.
 artikel
75 Pharmacogenetic determinants of toxicity and response in acute lymphoblastic leukemia 2002
 38 Supplement 6 p. S68-S69
2 p.
 artikel
76 Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours de Jonge, M.J.A.
 2002
 38 Supplement 6 p. 2407-2415
9 p.
 artikel
77 Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration Dittrich, Ch.
 2002
 38 Supplement 6 p. 1072-1080
9 p.
 artikel
78 Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer Kasai, T
 2002
 38 Supplement 6 p. 1871-1878
8 p.
 artikel
79 Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule Sessa, C.
 2002
 38 Supplement 6 p. 2388-2396
9 p.
 artikel
80 Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours Awada, A.
 2002
 38 Supplement 6 p. 2272-2278
7 p.
 artikel
81 Phase I and pharmacologic study of the macromolecular topoisomerase-I-inhibitor DE-310 given once every 2 or 6 weeks in patients with solid tumors 2002
 38 Supplement 6 p. S45-
1 p.
 artikel
82 Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases Grüschow, K
 2002
 38 Supplement 6 p. 367-374
8 p.
 artikel
83 Phase II study of E7070 in patients with metastatic melanoma (stage IV) 2002
 38 Supplement 6 p. S50-
1 p.
 artikel
84 Phase II trial of ZD0473 as second-line therapy in mesothelioma Giaccone, G
 2002
 38 Supplement 6 p. S19-S24
6 p.
 artikel
85 Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer Polee, M.B
 2002
 38 Supplement 6 p. 1495-1500
6 p.
 artikel
86 Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours Androulakis, N
 2002
 38 Supplement 6 p. 1992-1997
6 p.
 artikel
87 Phase I trial of recombinant human endostatin (rHu-endo) administered by continuous infusion (CI) intravenously (IV) in patients with solid tumors: a preliminary report 2002
 38 Supplement 6 p. S73-S74
2 p.
 artikel
88 Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer Corsi, D.C.
 2002
 38 Supplement 6 p. 527-534
8 p.
 artikel
89 Prescribing anti-cancer drugs in elderly cancer patients Monfardini, Silvio
 2002
 38 Supplement 6 p. 2341-2346
6 p.
 artikel
90 Primary systematic therapy in operable disease 2002
 38 Supplement 6 p. S128-S129
2 p.
 artikel
91 Product development of fenretinide, NSC 374551, intravenous formulation 2002
 38 Supplement 6 p. S21-
1 p.
 artikel
92 Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Van Glabbeke, M
 2002
 38 Supplement 6 p. 543-549
7 p.
 artikel
93 Proteolysis of xyotax by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS 2002
 38 Supplement 6 p. S129-
1 p.
 artikel
94 PTEN suppresses hyaluronic acid induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation 2002
 38 Supplement 6 p. S80-
1 p.
 artikel
95 Publisher's Note 2002
 38 Supplement 6 p. 1553-
1 p.
 artikel
96 Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer Kouloulias, Vassilis E.
 2002
 38 Supplement 6 p. 1849-1856
8 p.
 artikel
97 Radiobiological characteristics of solid tumours depending on the p53 status of the tumour cells, with emphasis on the response of intratumour quiescent cells Masunaga, S
 2002
 38 Supplement 6 p. 718-727
10 p.
 artikel
98 Raltitrexed in the treatment of elderly patients with advanced colorectal cancer Feliu, J
 2002
 38 Supplement 6 p. 1204-1211
8 p.
 artikel
99 Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma Rummel, M.J
 2002
 38 Supplement 6 p. 1739-1746
8 p.
 artikel
100 Referees—2002 2002
 38 Supplement 6 p. 2477-
1 p.
 artikel
101 Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients van Oosterom, A.T
 2002
 38 Supplement 6 p. 2397-2406
10 p.
 artikel
102 Ribozyme-PEI complex technology allows efficient down-regulation of gene expression in vitro and in vivo 2002
 38 Supplement 6 p. S146-
1 p.
 artikel
103 Role of MAPKs in heat-induced apoptosis 2002
 38 Supplement 6 p. S165-
1 p.
 artikel
104 Second primary cancers in laryngeal cancer patients in Slovenia, 1961–1996 Ećimović, P
 2002
 38 Supplement 6 p. 1254-1260
7 p.
 artikel
105 SELDI-TOF proteomic patterns of human and experimental brain tumors: potential for new biomarkers and for pharmaco-proteomic endpoints in anti-angiogenic therapy 2002
 38 Supplement 6 p. S73-
1 p.
 artikel
106 Session 2 S3. Approaches to identify low penetrance cancer susceptibility genes using mouse models de Koning, John P.
 2002
 38 Supplement 6 p. S5-
1 p.
 artikel
107 Session 10 S31. Fecal Occult Blood (FOB) screening — trial evidence, practice and beyond Rennert, Gad
 2002
 38 Supplement 6 p. S34-
1 p.
 artikel
108 Session 6 S18. Is mammography screening for breast cancer really not justifiable? Miller, Anthony B.
 2002
 38 Supplement 6 p. S21-
1 p.
 artikel
109 Session 6 S17. Political interpretation of scientific evidence: Case study of breast cancer screening policies around the world Rennert, Gad
 2002
 38 Supplement 6 p. S20-
1 p.
 artikel
110 Session 6 S19. Validity of screening mammography trials Feig, Stephen A.
 2002
 38 Supplement 6 p. S22-
1 p.
 artikel
111 Short Abstracts 2002
 38 Supplement 6 p. IFC-
1 p.
 artikel
112 Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma O'Hanlon, D.M
 2002
 38 Supplement 6 p. 2252-2257
6 p.
 artikel
113 Structure-activity relationships of platinum(II) phosphonate compounds for the treatment of bone malignancies 2002
 38 Supplement 6 p. S29-S30
2 p.
 artikel
114 Sun exposure and sun protection in young European children Severi, G
 2002
 38 Supplement 6 p. 820-826
7 p.
 artikel
115 Supraglottic and glottic carcinomas Hirvikoski, P
 2002
 38 Supplement 6 p. 1717-1723
7 p.
 artikel
116 Survival statistics "overly pessimistic" 2002
 38 Supplement 6 p. 2331-2335
5 p.
 artikel
117 Systemic treatment of colorectal cancer Tebbutt, N.C
 2002
 38 Supplement 6 p. 1000-1015
16 p.
 artikel
118 The achievements of the EORTC Lymphoma Group Raemaekers, J
 2002
 38 Supplement 6 p. 107-113
7 p.
 artikel
119 The angiogenic factor CYR61, a downstream effector of heregulin, protects breast cancer cells from paclitaxel-induced cell death through integrin alphav beta3 2002
 38 Supplement 6 p. S108-S109
2 p.
 artikel
120 The Children Leukemia Group Otten, J
 2002
 38 Supplement 6 p. 44-49
6 p.
 artikel
121 The EORTC Breast Cancer Group Therasse, P
 2002
 38 Supplement 6 p. 39-43
5 p.
 artikel
122 The EORTC Gastrointestinal Tract Cancer Group Anak, Ö
 2002
 38 Supplement 6 p. 65-70
6 p.
 artikel
123 The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance Parker, C
 2002
 38 Supplement 6 p. 2014-2019
6 p.
 artikel
124 The quality of survival after childhood cancer Jenney, M.E.M.
 2002
 38 Supplement 6 p. 1241-1250
10 p.
 artikel
125 The role of Chk1 signaling pathways in response to the topoisomerase I poison SN-38 2002
 38 Supplement 6 p. S134-
1 p.
 artikel
126 The role of secondary DNA structures in silencing transcription 2002
 38 Supplement 6 p. S115-
1 p.
 artikel
127 The silybin-phospholipid complex IdB 1016 inhibits human ovarian cancer growth in athymic nude mice 2002
 38 Supplement 6 p. S154-
1 p.
 artikel
128 The synthesis of hypoxia-selective nitroaromatic compounds as bioreductive drug delivery agents 2002
 38 Supplement 6 p. S120-
1 p.
 artikel
129 This Issues Topics 2002
 38 Supplement 6 p. ix-x
nvt p.
 artikel
130 This issue's topics 2002
 38 Supplement 6 p. ix-x
nvt p.
 artikel
131 Thyroid cancer after radiation exposure Rubino, C.
 2002
 38 Supplement 6 p. 645-647
3 p.
 artikel
132 TNFerade, an adenovector encoding the human tumor necrosis factor alpha gene, in soft tissue sarcoma in the extremity. safety and early efficacy data 2002
 38 Supplement 6 p. S141-S142
2 p.
 artikel
133 Transanal endoscopic microsurgery for rectal cancer de Graaf, E.J.R
 2002
 38 Supplement 6 p. 904-910
7 p.
 artikel
134 Trends in breast-conserving surgery in the Southeast Netherlands Gøtzsche, Peter C.
 2002
 38 Supplement 6 p. 1288-
1 p.
 artikel
135 Tyrosine kinases as targets for cancer therapy Levitzki, Alexander
 2002
 38 Supplement 6 p. S11-S18
8 p.
 artikel
136 Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group van Oosterom, Allan T.
 2002
 38 Supplement 6 p. S83-S87
5 p.
 artikel
137 Update on pharmacogenetics in cancer chemotherapy Innocenti, F.
 2002
 38 Supplement 6 p. 639-644
6 p.
 artikel
138 Use of high-dose cytarabine to enhance cisplatin cytotoxicity—effects on the response and overall survival rates of advanced head and neck cancer patients Jelić, S
 2002
 38 Supplement 6 p. 1478-1489
12 p.
 artikel
139 Use of OvaRex(r) MAb-b43.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as single agent post first-line therapy and in combination with chemotherapy in recurrent disease 2002
 38 Supplement 6 p. S137-
1 p.
 artikel
140 Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II study Morant, R
 2002
 38 Supplement 6 p. 1626-1632
7 p.
 artikel
141 Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer Pectasides, D
 2002
 38 Supplement 6 p. 1194-1200
7 p.
 artikel
142 Women who participate in spontaneous screening are not at higher risk for cervical cancer than women who attend programme screening Bos, A.B
 2002
 38 Supplement 6 p. 827-831
5 p.
 artikel
                             142 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland